Recent Quotes (30 days)

You have no recent quotes
chg | %

Trillium Therapeutics Inc  

(Public, CVE:SSS)   Watch this stock  
Find more results for SSS
Delayed:   3:58PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.14 - 0.74
Open     -
Vol / Avg. 0.00/243,705.00
Mkt cap 75.85M
P/E     -
Div/yield     -
EPS -0.08
Shares     -
Beta 1.41
Inst. own     -

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -6.60% -40.72%
Return on average equity -11.15% -69.93%
Employees 18 -
CDP Score - -


96 Skyway Ave
+1-416-5950627 (Phone)

Website links


Trillium Therapeutics Inc. (Trillium), formerly Stem Cell Therapeutics Corp., is a Canada-based immuno-oncology company developing therapies for the treatment of cancer. The Company's lead program, SIRPaFc, is an antibody-like protein that harnesses the innate immune system by blocking the activity of CD47, a molecule whose expression is increased on cancer cells to evade the host immune system. SIRPaFc is in pre-clinical development as a treatment for acute myeloid leukemia (AML). CD47 binds SIRPaFc on the surface of macrophages, and transmits a do-not-eat signal that protects cells from macrophage attack. The Company is also developing human monoclonal antibodies that block the activity of CD200, an immunosuppressive molecule. The Company's antibodies bind to human CD200 with high affinity, potently neutralize CD200 function in-vitro, and have anti-tumor activity in a human xenograft model.